Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

Archive ouverte

Dubois, Sydney | Viailly, Pierre-Julien | Mareschal, Sylvain | Bohers, Elodie | Bertrand, Philippe | Ruminy, Philippe | Maingonnat, Catherine | Jais, Jean-Philippe | Peyrouze, Pauline | Figeac, Martin | Molina, Thierry J. | Desmots, Fabienne | Fest, Thierry | Haioun, Corinne | Lamy, Thierry | Copie-Bergman, Christiane | Brière, Josette | Petrella, Tony | Canioni, Danielle | Fabiani, Bettina | Coiffier, Bertrand | Delarue, Richard | Peyrade, Frederic | Bosly, André | André, Marc | Ketterer, Nicolas | Salles, Gilles | Tilly, Hervé | Leroy, Karen | Jardin, Fabrice

Edité par CCSD ; American Association for Cancer Research -

International audience. Purpose: Next-generation sequencing (NGS) has detailed the genomic characterization of diffuse large B-cell lymphoma (DLBCL) by identifying recurrent somatic mutations. We set out to design a clinically feasible NGS panel focusing on genes whose mutations hold potential therapeutic impact. Furthermore, for the first time, we evaluated the prognostic value of these mutations in prospective clinical trials. Experimental Design: A Lymphopanel was designed to identify mutations in 34 genes, selected according to literature and a whole exome sequencing study of relapsed/refractory DLBCL patients. The tumor DNA of 215 patients with CD20(+)de novo DLBCL in the prospective, multicenter, and randomized LNH-03B LYSA clinical trials was sequenced to deep, uniform coverage with the Lymphopanel. Cell-of-origin molecular classification was obtained through gene expression profiling with HGU133+2.0 Affymetrix GeneChip arrays. Results: The Lymphopanel was informative for 96% of patients. A clear depiction of DLBCL subtype molecular heterogeneity was uncovered with the Lymphopanel, confirming that activated B-cell-like (ABC), germinal center B-cell like (GCB), and primary mediastinal B-cell lymphoma (PMBL) are frequently affected by mutations in NF-kappa B, epigenetic, and JAK-STAT pathways, respectively. Novel truncating immunity pathway, ITPKB, MFHAS1, and XPO1 mutations were identified as highly enriched in PMBL. Notably, TNFAIP3 and GNA13 mutations in ABC patients treated with RCHOP were associated with significantly less favorable prognoses. Conclusions: This study demonstrates the contribution of NGS with a consensus gene panel to personalized therapy in DLBCL, highlighting the molecular heterogeneity of subtypes and identifying somatic mutations with therapeutic and prognostic impact. (C) 2016 AACR.

Suggestions

Du même auteur

Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study

Archive ouverte | Dubois, Sydney | CCSD

International audience. 57th Annual Meeting of the American-Society-of-Hematology Location: Orlando, FL Date: DEC 05-08, 2015

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Archive ouverte | Dubois, Sydney | CCSD

International audience. Purpose:MYD88 mutations, notably the recurrent gain-of-function L265P variant, are a distinguishing feature of activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL), leading to co...

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and Non-L265P Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Archive ouverte | Dubois, Sydney | CCSD

International audience. Introduction: MYD88 mutations, notably the recurrent gain-of-function L265P variant, are a distinguishing feature of Activated B-Cell like (ABC) Diffuse Large B Cell Lymphoma (DLBCL), leading...

Chargement des enrichissements...